Document:

Exhibit 10.1

 

FIRST AMENDMENT TO EMPLOYMENT AGREEMENT

 

This First Amendment to the
Employment Agreement is entered into and is effective as of December 9, 2021, by and between CASI PHARMACEUTICALS, INC., a Delaware
corporation having its principal office at 9620 Medical Center Drive, Suite 300, Rockville, MD 20850 (the “Company”)
and ALEXANDER ZUKIWSKI (“Executive”).

 

RECITALS

 

WHEREAS, the Company and Executive
previously entered into that certain Employment Agreement dated April 3, 2017 (the “Agreement”); and

 

WHEREAS, the Company and Executive
desire to make certain amendments to the Agreement.

 

NOW, THEREFORE, in consideration
of the above premises and the following mutual covenants and conditions, the parties agree as follows:

 

		1.	Paragraph 1 of the Agreement is hereby amended in its entirety and restated as follows:

 

Employment; Position and Duties; Other
Service. Subject to the terms hereof, the Company hereby agrees to employ Executive during the Term (as hereafter defined) to act
as, and to exercise all of the powers and functions of, its Chief Medical Officer, Executive Vice-President and to perform such acts and
duties and to generally furnish such services to the Company and its subsidiaries as is customary for a senior executive management person
with a similar position in like companies. Among other things, and subject to change at the discretion of the Board of Directors (the
 “Board”), the President and the Chief Executive Officer (the “CEO”), Executive shall play a leading
role in developing, advocating and executing the Company’s overall clinical development and regulatory plan. Executive will also
be a key member of the Company’s business development team, including participating in the clinical and medical evaluation of business
development opportunities, and in the strategic scouting and searching for in-license opportunities from the medical community. Executive
will from time to time participate in the Company’s finance and investment relations activities, and attend and make corporate presentations
in conferences and investor meetings as requested from time to time by the President or CEO. Executive shall also assume responsibilities
for supervision and management of the Rockville, Maryland office, supervision of the U.S. based non-finance staff members and their responsibilities
(legal, investor relations, public relations, information technology, office maintenance, human resources, etc.) and investor calls and
inquiries. Executive shall report directly to the CEO, and have such other powers, duties and responsibilities as the President, CEO and
the Board shall from time to time reasonably prescribe. Executive hereby agrees to accept such employment and shall perform and discharge
faithfully, diligently, and to the best of his abilities such duties and responsibilities and shall devote sufficient working time and
efforts to the business and affairs of the Company and its subsidiaries. During the Term, Executive will be permitted to (i) maintain
a clinical oncology practice, (ii) provide consulting services, up to three (3) days per month, and (iii) serve on the board of directors
or the Scientific Advisory Board of companies that are not Competing Companies (as hereafter defined); provided, in each case, that such
service does not significantly interfere with the performance of Executive’s responsibilities as an employee of the Company; and
provided, further, that such service shall be subject to the consent of the CEO, which consent may be withdrawn in whole or in part at
any time. Upon the request of the CEO, but no less frequently than quarterly, Executive shall provide a listing of the companies for which
Executive provides such services.

 

     

     

    

 

		2.	Paragraph 2 of the Agreement is hereby amended and restated in its entirety as follows:

 

While Executive is employed by the Company
during the Term, Executive shall conduct his duties and responsibilities hereunder from the executive office located in Rockville, Maryland
and from the Company’s office located in Beijing, China (except for routine and customary business travel), or from such other location
as approved by the President or CEO. Executive may participate in a remote work policy, to the extent established by the Company, or as
approved by the President or CEO.

 

		3.	Paragraph 3(a) of the Agreement is hereby amended and restated in its entirety as follows:

 

Base Salary. While the Company
employs Executive during the Term, the Company shall pay to Executive an annual base salary (“Base Salary”) of no less
than US$522,000, effective as of August 16, 2021, payable in accordance with the Company’s customary payroll policy for its executives.

 

		4.	Paragraph 3(b) of the Agreement is hereby amended by replacing “US$400,000” with “US$522,000”.

 

		5.	The Agreement is hereby amended to add a new paragraph 3(f) of the Agreement, which reads as follows:

 

Special Bonus. Executive shall
be entitled to receive a special one-time bonus in the amount of US$500,000, which shall be payable upon certification by the compensation
committee of the Board, in its sole discretion, that a Phase II study of CID-103 demonstrates a Proof of Principle that would support
a decision to initiate a Phase III clinical trial, provided that Executive is employed on the date of such certification. Such bonus,
if any, shall be paid within sixty (60) days of such certification.

 

     

     

    

 

		6.	The fifth sentence of paragraph 8(d) of the Agreement is hereby amended and restated to read as follows:

 

However, in addition to the above, if
Executive is terminated by the Company (i) pursuant to this subparagraph 8(d) or (ii) upon the Company’s nonextension of the Term
in accordance with Section 4 (provided that Executive is then willing and able to continue to provide services under terms and conditions
substantially similar to those in this contract) and for any reason other than Cause, death or Disability, the Company shall (A) pay Executive
a payment equal to the amount of his Base Salary that would have been payable had Executive remained employed through the last day of
the twelve (12) months following the month in which termination occurred, which payment shall be divided into twelve (12) equal installments
and paid monthly in the twelve (12) subsequent months following such termination; and (B) a lump sum payment in an amount equal to twelve
(12) months of COBRA premiums for the level of coverage that Executive had in effect as of immediately prior to his termination.

 

Except as expressly amended
herein, all other provisions of the Agreement shall continue in effect and be unaffected hereby.

 

 

 

IN WITNESS WHEREOF, the parties
have set their signatures on the date first written above.

 

 

	
    THE COMPANY
	 	
    EXECUTIVE 

	 	 	 	 
	
    CASI PHARMACEUTICALS, INC.

     
	 	 
	 	 	 	 
	 	 	 	 
	By:	/s/ Larry (Wei) Zhang	 	 
	Name:	Larry (Wei) Zhang	 	/s/ ALEXANDER ZUKIWSKI
	Its:	PresidentExhibit 10.3

 

FIRST AMENDMENT TO CHANGE IN CONTROL AGREEMENT

 

This First Amendment to the
Change in Control Agreement is entered into and is effective as of December 9, 2021, by and between CASI PHARMACEUTICALS, INC.,
(the “Company”) and ALEXANDER ZUKIWSKI (“Executive”).

 

RECITALS

 

WHEREAS, the Company and Executive
previously entered into that certain Change in Control Agreement dated April 3, 2017 (the “Agreement”); and

 

WHEREAS, the Company and Executive
desire to make certain amendments to the Agreement.

 

NOW, THEREFORE, in consideration
of the above premises and the following mutual covenants and conditions, the parties agree as follows:

 

		1.	Section 3.1 of the Agreement is hereby amended in its entirety and restated as follows:

 

Severance Payment. In lieu of any
further salary payments to the Executive for periods subsequent to the Date of Termination, including, without limitation, any severance
payments under the Employment Agreement, the Company shall pay to the Executive a lump sum severance payment, in cash, without discount.
The severance payment shall be equal to the sum of (a) the product of (x) twelve (12) months and (y) the Executive's Monthly Base Salary
and (b) the Executive's Average Bonus (the “Full Severance Payment”).

 

		2.	Section 3.3 of the Agreement is hereby amended in its entirety and restated as follows:

 

Lump Sum Equal to COBRA Premiums.
The Company shall pay to Executive a lump sum payment in an amount equal to twelve (12) months of COBRA premiums for the level of coverage
that Executive had in effect as of immediately prior to his termination (provided that such lump sum payment shall be equal to only six
(6) months of COBRA premiums for the level of coverage that Executive had in effect as of immediately prior to his termination if the
Date of Termination is within six (6) months of the commencement of employment with the Company by the Executive).

 

Except as expressly amended
herein, all other provisions of the Agreement shall continue in effect and be unaffected hereby.

 

     

     

    

 

IN WITNESS WHEREOF, the parties
have set their signatures on the date first written above.

 

 	
    THE COMPANY
	 	
    EXECUTIVE 

	 	 	 	 
	
    CASI PHARMACEUTICALS, INC.

     
	 	 
	 	 	 	 
	 	 	 	 
	By:	/s/ Larry (Wei) Zhang	 	 
	Name:	Larry (Wei) Zhang 	 	/s/ ALEXANDER ZUKIWSKI
	Its:	Presidenta2022stipfinal

2022 Short Term Incentive Program (STIP) Plan Provision Terms of the Plan Program Participation  Section 16b Officers  All salaried and hourly-paid employees eligible for variable compensation Financial Objectives  Corporate – Adjusted EBITDA, Levered Free Cash Flow  Chemicals (Combined CAPV and Epoxy) – Adjusted EBITDA, Adjusted Cash Flow  Winchester – Adjusted EBITDA, Adjusted Cash Flow Non-Financial Objectives  Key strategic objectives including Safety, Environmental, Sustainability, People and Valuation objectives Weighting  Corporate – Adjusted EBITDA (50%); Levered Free Cash Flow (30%); Non-Financial (20%)  Divisions –Adjusted EBITDA (60%); Cash Flow (20%); Non-Financial (20%) Target Setting  Targets established by Compensation Committee of the Board of Directors Leverage  Threshold Value Established by Compensation Committee  Maximum Value Established by Compensation Committee  Maximum payout of financial targets = 225%   Maximum payout of non-financial targets = 100%  Maximum total payout of financial and non-financial targets = 200%  No individual award may exceed 200% of target Financial Objectives Payouts  Payout at Target – 100%   Payout at Threshold – 50%   Payout Below Threshold – Zero    Payouts scale down approximately 1.8% for every 1% below target; Scale up approximately 6.25% for every  1% above target   Payout at Maximum for financial objectives is 180%, based on weighting.  If Adjusted EBITDA threshold not met, all financial payouts are discretionary. Non-Financial Objectives  Payouts  Payout on achievement of Non-Financial Objectives is independent of performance on Financial Objectives  and determined by Compensation Committee.     Payout at Maximum for non-financial objectives is 20%, based on weighting.  Exhibit 10.1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}]]